Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Andrea H, Bild"'
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-17 (2024)
Abstract Fibroblast growth factors (FGFs) control various cellular functions through fibroblast growth factor receptor (FGFR) activation, including proliferation, differentiation, migration, and survival. FGFR amplification in ER + breast cancer pati
Externí odkaz:
https://doaj.org/article/9d8a1a28a88c466a86db64bb029178e3
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Tumors are comprised of subpopulations of cancer cells that harbor distinct genetic profiles and phenotypes that evolve over time and during treatment. By reconstructing the course of cancer evolution, we can understand the acquisition of th
Externí odkaz:
https://doaj.org/article/32809e00495645f1b0e0865e48743292
Autor:
Rena Emond, Jason I. Griffiths, Vince Kornél Grolmusz, Aritro Nath, Jinfeng Chen, Eric F. Medina, Rachel S. Sousa, Timothy Synold, Frederick R. Adler, Andrea H. Bild
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract The interplay of positive and negative interactions between drug-sensitive and resistant cells influences the effectiveness of treatment in heterogeneous cancer cell populations. Here, we study interactions between estrogen receptor-positive
Externí odkaz:
https://doaj.org/article/ace0baddb0824ad0a9092e60d8e05400
Autor:
Elena Farmaki, Aritro Nath, Rena Emond, Kimya L Karimi, Vince K Grolmusz, Patrick A Cosgrove, Andrea H Bild
Publikováno v:
eLife, Vol 12 (2023)
The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inh
Externí odkaz:
https://doaj.org/article/c96b28ace81548d2be96b829718494be
Publikováno v:
Molecular Systems Biology, Vol 18, Iss 6, Pp 1-16 (2022)
Abstract Advanced and metastatic estrogen receptor‐positive (ER+) breast cancers are often endocrine resistant. However, endocrine therapy remains the primary treatment for all advanced ER+ breast cancers. Treatment options that may benefit resista
Externí odkaz:
https://doaj.org/article/5b6589b8ae604152b37754057a310450
Autor:
Xiaomeng Huang, Yi Qiao, Samuel W. Brady, Rachel E. Factor, Erinn Downs-Kelly, Andrew Farrell, Jasmine A. McQuerry, Gajendra Shrestha, David Jenkins, W. Evan Johnson, Adam L. Cohen, Andrea H. Bild, Gabor T. Marth
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-18 (2021)
Abstract Background Metastatic breast cancer is a deadly disease with a low 5-year survival rate. Tracking metastatic spread in living patients is difficult and thus poorly understood. Methods Via rapid autopsy, we have collected 30 tumor samples ove
Externí odkaz:
https://doaj.org/article/6f48789139544631a3eabb9929b6e5ba
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Recent advances in single cell RNA sequencing (scRNA-seq) technologies have been invaluable in the study of the diversity of cancer cells and the tumor microenvironment. While scRNA-seq platforms allow processing of a high number of cells, uneven rea
Externí odkaz:
https://doaj.org/article/5aaf248867914b4e933380b0059d5619
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Endocrine therapy remains the primary treatment choice for ER+ breast cancers. However, most advanced ER+ breast cancers ultimately develop resistance to endocrine. This acquired resistance to endocrine therapy is often driven by the activation of th
Externí odkaz:
https://doaj.org/article/12b7c7e610184dfe834172148ac48ce3
Autor:
Aritro Nath, Patrick A. Cosgrove, Hoda Mirsafian, Elizabeth L. Christie, Lance Pflieger, Benjamin Copeland, Sumana Majumdar, Mihaela C. Cristea, Ernest S. Han, Stephen J. Lee, Edward W. Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam L. Cohen, Philip Moos, Jeffrey T. Chang, David D. L. Bowtell, Andrea H. Bild
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
High-grade serous ovarian cancer (HGSOC) is prone to developing resistance to treatment. Here, the authors use single-cell RNA-seq and an analysis of archetypes, and find that shifts in metabolism and proliferation are associated with the response to
Externí odkaz:
https://doaj.org/article/ae3e02320d4947c59945469a2cf43f04
Autor:
Vince Kornél Grolmusz, Jinfeng Chen, Rena Emond, Patrick A. Cosgrove, Lance Pflieger, Aritro Nath, Philip J. Moos, Andrea H. Bild
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer. However, cancers can advance due to dru
Externí odkaz:
https://doaj.org/article/e5a4169ce9df446384fbab9e6ed1de17